Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00723099 · ClinicalTrials.gov registry record · Phase 2

Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer

A Phase 2 study of Lymphoma and Acute Myeloid Leukemia, sponsored by Fred Hutchinson Cancer Center.

Completed
Registry status
Phase 2
Development phase
73
Enrollment target
6
Study locations

NCT00723099: Completed Phase 2 study of Lymphoma and Acute Myeloid Leukemia, sponsored by Fred Hutchinson Cancer Center.

NCT00723099 is a Phase 2 study of Lymphoma and Acute Myeloid Leukemia that has completed, run by Fred Hutchinson Cancer Center. The registered enrollment target is 73 participants, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (85% lower). The trial reports 6 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00723099, a Phase 2 study of Lymphoma and Acute Myeloid Leukemia, has completed, sponsored by Fred Hutchinson Cancer Center.

COMPLETED
Registry status
Phase 2
Development phase
73 participants
Enrollment target
6
Study locations

Study Summary

This phase II trial is studying how well umbilical cord blood transplant from a donor works in treating patients with hematological cancer. Giving chemotherapy and total-body irradiation (TBI) before a donor umbilical cord blood transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from an unrelated donor, that do not exactly match the patient's blood, are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells (called graft-versus-host disease). Giving cyclosporine and mycophenolate mofetil before and after transplant may stop this from happening.

Primary Outcome

Kaplan-Meier and cumulative incidence estimates will be used.

Conditions Studied

Lymphoma Acute Myeloid Leukemia Myelodysplastic Syndrome Acute Lymphoblastic Leukemia Myeloproliferative Neoplasm Mixed Phenotype Acute Leukemia Chronic Myelogenous Leukemia Chronic Phase Chronic Myelogenous Leukemia Indolent Non-Hodgkin Lymphoma Aggressive Non-Hodgkin Lymphoma

Interventions

  • DRUG Cyclophosphamide
  • OTHER Laboratory Biomarker Analysis
  • DRUG Fludarabine Phosphate
  • DRUG Cyclosporine
  • PROCEDURE Allogeneic Hematopoietic Stem Cell Transplantation

Study Locations (6)

Colorado

  • University of Colorado Hospital - Aurora
  • Colorado Blood Cancer Institute - Denver

Washington

  • VA Puget Sound Health Care System - Seattle
  • Fred Hutch/University of Washington Cancer Consortium - Seattle

Utah

  • LDS Hospital - Salt Lake City

Wisconsin

  • Froedtert and the Medical College of Wisconsin - Milwaukee

Trial Details

FieldValue
Enrollment Target 73 participants
Start Date 2008-06-25
Est. Completion 2018-07-31
Phase Phase 2
Fred Hutchinson Cancer Center

483 total trials

What the finished NCT00723099 record still lists

NCT00723099 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 73 participants, a relatively small participant target, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (85% lower).

The record links to 10 conditions, with Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which Cyclophosphamide is the first listed.

NCT00723099 lists 6 locations in 4 states (Colorado, Washington, Utah).

Frequently Asked Questions

What is clinical trial NCT00723099 about?

NCT00723099 is a clinical study titled "Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer". This phase II trial is studying how well umbilical cord blood transplant from a donor works in treating patients with hematological cancer. Giving chemotherapy and total-body irradiation (TBI) before a donor umbilical cord blood transplant helps stop the growth of cancer and abnormal cells and helps...

What is the current status of trial NCT00723099?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 73 participants. The study started on 2008-06-25. Estimated completion is 2018-07-31.

What conditions does trial NCT00723099 study?

This clinical trial studies the following conditions: Lymphoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, Myeloproliferative Neoplasm.

What interventions are being tested in trial NCT00723099?

The interventions under investigation include: Cyclophosphamide (DRUG), Laboratory Biomarker Analysis (OTHER), Fludarabine Phosphate (DRUG), Cyclosporine (DRUG), Allogeneic Hematopoietic Stem Cell Transplantation (PROCEDURE).

Who is sponsoring clinical trial NCT00723099?

This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00723099 being conducted?

This trial has 6 study locations across Colorado, Utah, Washington, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00723099's enrollment target sits among peer trials

73 115th of 299 higher than 185 of 299 other Lymphoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03661307 · 73 participants · Phase 1

    Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

  • NCT05386108 · 73 participants · Phase 1

    Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer

  • NCT05961592 · 73 participants · Phase 1

    R-2487 in Patients With Rheumatoid Arthritis

  • NCT06150664 · 73 participants · Phase 1

    A Phase 1 of CTX-8371 in Patients With Advanced Malignancies

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT00723099, the US trial registry maintained by the National Library of Medicine. NCT00723099 (small enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.